SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

MGL-2086

MDGL·MADRIGAL PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
Unknown, Phase 1 dosing only began June 2026; Phase 2 anticipated 2027, so approval (if trials succeed) is realistically many years away (early-to-mid 2030s).
Why 2/10
MGL-2086 is a Phase 1 program with no hard, dated binary in the next ~12 months, SAD/MAD dosing runs through 2026 and data will only inform a Phase 2 combination study (with resmetirom) anticipated for 2027, and it is a small part of a commercial company whose share price is driven by Rezdiffra sales, so the score sits at the bottom of the scale (0-2).
Actionable Insight NEUTRAL

Do not trade MDGL on MGL-2086, there is no dated readout to trade; near-term price action will be driven by Rezdiffra's commercial ramp and the 2027 MAESTRO F4c cirrhosis outcomes readout. Watch for (1) any early Phase 1 SAD/MAD data release for MGL-2086 (likely 2027), (2) FDA feedback on the Rezdiffra/MGL-2086 Phase 2 combo design, and (3) progress of rival oral GLP-1s (notably Lilly's orforglipron, the molecule this is derived from), which caps the strategic upside.

Price Chart

Loading chart...

Executive Summary

MGL-2086 (formerly SYH2086) is an oral small-molecule GLP-1 receptor agonist, a derivative of Eli Lilly's orforglipron, that Madrigal exclusively licensed from China's CSPC Pharmaceutical Group in July 2025 for $120M upfront and up to $2B in milestones plus royalties, to combine with its approved MASH drug Rezdiffra. Dosing in the Phase 1 single-ascending-dose trial began in June 2026, on schedule, with Phase 2 combination data targeted for 2027. It is a strategically sensible but very early, unproven program at a commercial company whose stock (MDGL, ~$467 as of July 31, 2026) is driven by Rezdiffra's sales ramp, so MGL-2086 itself carries no near-term binary catalyst.

How It Works

MGL-2086 is a pill that mimics the natural gut hormone GLP-1, the same biological target as popular injected weight-loss drugs like Ozempic/Wegovy. It suppresses appetite, slows digestion and improves metabolic markers. Madrigal's plan is to pair it with its approved liver drug Rezdiffra so MASH (fatty liver disease) patients get weight/metabolic benefit plus direct liver benefit in one daily pill.

Trial Status

Phase 1 single ascending dose (SAD) trial dosing initiated June 2026, as part of the Rezdiffra/MGL-2086 combination program in MASH; SAD and multiple ascending dose (MAD) studies ongoing through 2026, with results expected to inform a Phase 2 combination study with resmetirom anticipated in 2027. No efficacy data reported yet.

The Two-Sided Case

▲ Bull Case4
Combining an oral GLP-1 with Rezdiffra could yield a once-daily, best-in-disease oral pill for MASH, Madrigal explicitly frames it that way, and a Phase 2 combo study with resmetirom is planned for 2027.
Cheap optionality: exclusive global rights cost just $120M upfront (up to $2B in milestones plus royalties), and the mechanism is validated by the huge GLP-1 class, reducing mechanism risk.
Execution is on schedule: Phase 1 SAD dosing initiated June 2026 as planned, and SAD/MAD data are expected to inform the Phase 2 design.
Backed by a commercial-stage balance sheet: Rezdiffra Q2 2026 net sales were $364.3M (+71% YoY) with 49,000+ patients on therapy, and cash + marketable securities were ~$817.9M as of March 31, 2026.
▼ Bear Case4
No clinical data yet, dosing only began June 2026; tolerability and efficacy of an oral GLP-1 specifically in MASH patients are unproven, and most early-stage GLP-1 programs never reach market.
Brutal competition: MGL-2086 is an orforglipron derivative, and Lilly's orforglipron itself is far ahead in late-stage trials, while Novo's oral semaglutide is already approved, MGL-2086 would be a late entrant in a crowded oral-GLP-1 race.
Long, expensive, risky road: Phase 2 anticipated 2027 at earliest, approval many years away, with up to $2B in milestone and royalty obligations owed to CSPC; Madrigal also booked a ~$117M one-time R&D charge for the license in Q3 2025.
Not a near-term share-price driver: MDGL is valued on Rezdiffra execution and the 2027 F4c cirrhosis outcomes readout, not a Phase 1 pipeline asset, and at ~$467 with a 52-week range of $299.17-$615, expectations are already high.

Upcoming Catalysts

  • Phase 1 SAD/MAD data for MGL-2086 (no firm date; expected to inform Phase 2 design, likely 2027)
  • FDA consultations on Phase 2 combination trial design for Rezdiffra/MGL-2086 (2026)
  • Phase 2 combination trial initiation, anticipated 2027
  • Context (not MGL-2086): Rezdiffra Phase 3 MAESTRO F4c cirrhosis outcomes readout expected 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MADRIGAL PHARMACEUTICALS, INC. 8-K MDGL ·Originating report

Sources · 17

Hover a chip for the title
1 ir.madrigalpharma.com2 madrigalpharma.com3 ir.madrigalpharma.com4 sec.gov5 fiercebiotech.com6 ir.madrigalpharma.com7 nasdaq.com8 ir.madrigalpharma.com9 markets.businessinsider.com10 marketbeat.com11 finance.biggo.com12 biospace.com13 msn.com14 stocktitan.net15 adisinsight.springer.com16 pharmexec.com17 ropesgray.com